Similarly, the combination of T-DM1 and anti PD1/CTLA4 agents fostered both innate and adaptive immune response, ultimately resulting in tumor rejection in a HER2-expressing orthotopic tumor model [34]. The gene discussed is ERBB2; the disease is neoplasm.